DaVita Projects Q3 EPS Growth of 50.6% YoY to $3.78 with Forward P/E at 12.1
Question
DaVita Projects Q3 EPS Growth of 50.6% YoY to $3.78 with Forward P/E at 12.1
Direct answer
Outsized EPS expansion against a discounted 12.1 forward P/E multiple drives multiple rerating at DVA toward the healthcare industry benchmark. — bullish pressure on DVA via earnings per share growth flowing into forward price-to-earnings multiple expansion.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-04
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “DaVita Projects Q3 EPS Growth of 50.6% YoY to $3.78 with Forward P/E at 12.1”, revision 1, evidence through 2026-10-04. https://marketontology.com/catalysts/2026-10-04/davita-projects-q3-eps-growth-of-50-6-yoy-to-3-78-with-forward-p-e-at-12-1-093b3b
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| DVA | ▲Bull | 1–4 weeks | earnings per share growth flowing into forward price-to-earnings multiple expansion | 60 |
DaVita Projects Q3 EPS Growth of 50.6% YoY to $3.78 with Forward P/E at 12.1
Outsized EPS expansion against a discounted 12.1 forward P/E multiple drives multiple rerating at DVA toward the healthcare industry benchmark. — bullish pressure on DVA via earnings per share growth flowing into forward price-to-earnings multiple expansion.
Projected Q3 earnings of $3.78 per share represents 50.6% YoY growth at 12.1 forward P/E.
- SourceProjected Q3 earnings of $3.78 per share represents 50.6% YoY growth at 12.1 forward P/E.
- TransmissionOutsized EPS expansion against a discounted 12.1 forward P/E multiple drives multiple rerating at DVA toward the healthcare industry benchmark.
- SummaryDaVita is forecast to deliver 50.6% year-over-year earnings growth in Q3 to $3.78 per share. Shares closed at $178.69, trading at 12.1 times forward earnings versus a peer group average of 19.68. Operating performance reflects ongoing clinical cost containment and treatment volume stability.
- DVADirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Sector rotation or peer guidance may override single-name reaction
- DVA closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- DVA price vs. pre-event level
- DVA volume vs. 20-day average
- Sector ETF read-through
- Options implied volatility crush
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- DaVita HealthCare (DVA) Laps the Stock Market: Here's Why · Zacks Investment Research · 2026-10-02
Related catalysts
- 2026-10-11DaVita Projects 50.6% Quarterly EPS Growth at 12.15x Forward Earnings MultipleDVA
- 2026-10-11DaVita Outperforms S&P 500 on Projected 50.6% Dialysis EPS ExpansionDVA
- 2026-10-11DaVita Outperforms S&P 500 on Projected 50.6% Dialysis EPS ExpansionDVA XLV+3.45%
- 2026-10-11DaVita Projects 50.6% Quarterly EPS Growth at 12.15x Forward Earnings MultipleDVA
- 2026-10-10DaVita Outpaces S&P 500 on Forecast 50.6 Percent Quarterly EPS GrowthDVA SPY-1.97%
- 2026-10-10DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS GrowthDVA
- 2026-10-10DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS GrowthDVA
- 2026-10-10DaVita Gains as Forward P/E Holds at 12.15x Against 50.6% Projected EPS GrowthDVA
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.